首页|期刊导航|中国当代医药|非小细胞肺癌组织预后的影响因素分析

非小细胞肺癌组织预后的影响因素分析OA

Analysis of prognostic factors in non-small cell lung cancer

中文摘要英文摘要

目的 探讨影响非小细胞肺癌(NSCLC)患者预后的相关因素,为术后生存评估提供依据.方法 选取 2020 年10月至2022年5月在辽宁省健康产业集团阜新矿总医院接受手术的106例NSCLC患者作为研究对象,随访3年统计总生存率,取术中部分 NSCLC 组织,采用免疫组化检测 B 细胞易位基因-2(BTG-2)、甲状腺激素受体相互作用蛋白-6(TRIP-6)蛋白表达.Kaplan-Meier 法绘制 BTG-2、TRIP-6 蛋白阳性与阴性患者生存曲线,根据预后分为死亡组(n=47)与存活组(n=59).采用单因素及多因素 Cox 回归分析 NSCLC 患者预后的影响因素.结果 106 例 NSCLC 患者的生存率为 55.66%(59/106).其中,BTG-2 蛋白阳性患者的生存率高于 BTG-2 蛋白阴性者,TRIP-6蛋白阳性患者的生存率低于TRIP-6蛋白阴性者,差异有统计学意义(P<0.05).死亡组肿瘤大小≥3 cm比例、低分化比例、TNM Ⅲ期比例、淋巴结转移比例、TRIP-6 蛋白阳性比例大于存活组,BTG-2 蛋白阳性比例低于存活组,差异有统计学意义(P<0.05).低分化(HR=2.055,95%CI:1.101~3.835,P=0.024)、TNM Ⅲ期(HR=1.971,95%CI:1.089~3.568,P=0.025)、淋巴结转移(HR=2.228,95%CI:1.092~4.548,P=0.028)、TRIP-6 蛋白阳性表达(HR=2.242,95%CI:1.213~4.145,P=0.010)为 NSCLC 患者死亡的独立危险因素,BTG-2 蛋白阳性表达(HR=0.315,95%CI:0.110~0.899,P=0.031)为 NSCLC 患者死亡的独立保护因素.结论 NSCLC 组织中 BTG-2、TRIP-6阳性表达与不良预后相关,可能成为评估 NSCLC患者预后的新型标志物.

Objective To explore the factors influencing the prognosis of patients with non-small cell lung cancer(NSCLC),and to provide a basis for postoperative survival assessment.Methods A total of 106 NSCLC patients who underwent surgery at Fuxin General Hospital of Liaoning Health Industry Group from October 2020 to May 2022 were selected as the research subjects.The total survival rate was statistically analyzed over a 3-year follow-up period.Part of NSCLC tissues from the operation were taken and the protein expressions of B-cell translocation gene-2(BTG-2)and thyroid hormone receptor interacting protein-6(TRIP-6)were detected by immunohistochemistry.The survival curves of patients with positive and negative BTG-2 and TRIP-6 protein expressions were plotted using the Kaplan-Meier method.The patients were divided into the death group(n=47)and the survival group(n=59)based on the prognosis.Univariate and multivariate Cox regression analyses were used to investigate the influencing factors of the prognosis of NSCLC patients.Results The survival rate of 106 NSCLC patients was 55.66%(59/106).Among them,the survival rate of patients with positive BTG-2 protein was higher than that of patients with negative BTG-2 protein,and the survival rate of patients with positive TRIP-6 protein was lower than that of patients with negative TRIP-6 protein,with statistically significant differences(P<0.05).The proportion of tu-mor size≥3 cm,the proportion of poorly differentiated,the proportion of TNM stage Ⅲ,the proportion of lymph node metas-tasis,and the proportion of positive TRIP-6 protein in the death group were greater than those in the survival group,while the proportion of positive BTG-2 protein in the death group was lower than that in the survival group.The differences were statistically significant(P<0.05).Poor differentiation(HR=2.055,95%CI:1.101-3.835,P=0.024),TNM stage Ⅲ(HR=1.971,95%CI:1.089-3.568,P=0.025),lymph node metastasis(HR=2.228,95%CI:1.092-4.548,P=0.028),and positive TRIP-6 protein expression(HR=2.242,95%CI:1.213-4.145,P=0.010)were independent risk factors for the death of NSCLC patients,while positive BTG-2 protein expression(HR=0.315,95%CI:0.110-0.899,P=0.031)was an independent protective factor for the death of NSCLC patients.Conclusion In the NSCLC tissue,positive BTG-2 and expression TRIP-6 are associated with poor prognosis,and they may become new markers for evaluating the prognosis of NSCLC patients.

邢涪涵;崔贵;曹建阔

辽宁省健康产业集团阜新矿总医院胸心血管外科,辽宁 阜新 123000辽宁省健康产业集团阜新矿总医院胸心血管外科,辽宁 阜新 123000辽宁省健康产业集团阜新矿总医院胸心血管外科,辽宁 阜新 123000

医药卫生

非小细胞肺癌B细胞易位基因-2甲状腺激素受体相互作用蛋白-6预后

Non-small cell lung cancerB-cell translocation gene-2Thyroid hormone receptor interacting protein-6 Prognosis

《中国当代医药》 2026 (13)

52-55,60,5

辽宁省卫生健康委科研课题项目(202001077).

10.3969/j.issn.1674-4721.2026.13.11

评论